November 22, 2024: The ULT2 key-paper "Re-purposing zidovudine and 5-fluoro-2’-deoxyuridine as antibiotic drugs made possible by synergy with both trimethoprim and the mitochondrial toxicity-reducing agent uridine" was accepted for publication in Journal of Antimicrobial Chemotherapy.
July 5, 2024: The ULT3 patent was granted in China.
May 21, 2024: The ULT3 patent was granted in Japan.
May 14, 2024: The ULT3 patent was granted in the US.
March 19, 2024: The ULT2 patent was granted in Canada.
March 6, 2023: Ultupharma recieved the first batch of ULT4-compounds synthesized by CC4CARB.
October 20, 2022: The ULT2 patent was granted in Australia.
September 27, 2022: The NIAID approved that CC4CARB will design and synthesize a compound library based on a scaffold proposed by Ultupharma, to be used in Ultupharma’s antibacterial drug discovery program (ULT4).
June 15, 2022: The ULT2 patent was accepted in Australia.
June 1, 2022: The NIH NIAID CC4CARB initiative lead by RTI International has selected a scaffold proposal submitted by Ultupharma. Upon formal approval by NIAID, CC4CARB will design and synthesize a compound library based on the proposed scaffold which in turn will be used in Ultupharma’s antibacterial drug discovery program (ULT4).
October 29, 2021: The ULT2 patent was granted in China.
October 15, 2021: The ULT2 patent was granted in Hong Kong.
June 30, 2021: The ULT2 patent was granted in Europe.
June 9, 2021: The ULT2 patent was granted in Japan.
March 4, 2021: The intention to grant the ULT2 patent in Europe was issued.
February 25, 2021: The key-paper "Selective Isolation of Multidrug-Resistant Pedobacter spp., Producers of Novel Antibacterial Peptides" by Joakim Bjerketorp, Jolanta J. Levenfors, Christina Nord, Bengt Guss, Bo Öberg, and Anders Broberg, was published in Frontiers in Microbiology, doi.org/10.3389/fmicb.2021.642829. This paper describes our novel approach which resulted in the isolation of the multidrug-resistant bacteria producing the ULT3-peptides.
February 13, 2021: The paper "In‑peptide amino acid racemization via inter‑residue oxazoline intermediates during acidic hydrolysis", by Anders Broberg, Christina Nord, Jolanta J. Levenfors, Joakim Bjerketorp, Bengt Guss and Bo Öberg, was published in the journal Amino Acids, doi.org/10.1007/s00726-021-02951-7.
December 07, 2020: The paper "Tetramic acid based alkaloids from Aspergillus amoenus Roberg strain UP197 – antibiotic properties and new pyranterreones.", by Christina Nord, Jolanta J. Levenfors, Joakim Bjerketorp, Bengt Guss, Bo Öberg, and Anders Broberg, was published in the journal Natural Products Research. doi.org/10.1080/14786419.2020.1855643.
November 10, 2020: The grant of the ULT2 continuation-in-part in the US (US10828317) was published.
November 10, 2020: The grant of the ULT2 patent in the US (US10828316) was published.
October 14, 2020: A paper describing the ULT3-peptides was published in ACS Chemical Biology: Isopedopeptins A–H: Cationic Cyclic Lipodepsipeptides from Pedobacter cryoconitis UP508 Targeting WHO Top-Priority Carbapenem-Resistant Bacteria. Authors: Christina Nord, Joakim Bjerketorp, Jolanta J. Levenfors, Sha Cao, Adam A. Strömstedt, Bengt Guss, Rolf Larsson, Diarmaid Hughes, Bo Öberg, and Anders Broberg. doi.org/10.1021/acschembio.0c00568
September 29, 2020: The grant of the ULT3 patent in Sweden (SE543054) was published.
September 16, 2020: Notice of Allowance for the ULT2 patent in the US was issued.
September 15, 2020: Notice of Allowance for ULT2 continuation-in-part in the US was issued.
May 21, 2020: A paper in The Journal of Antibiotics was published: Antibacterial pyrrolidinyl and piperidinyl substituted 2,4-diacetylphloroglucinols from Pseudomonas protegens UP46. doi: 10.1038/s41429-020-0318-1 Authors: Jolanta J. Levenfors, Christina Nord, Joakim Bjerketorp, Jerry Ståhlberg, Rolf Larsson, Bengt Guss, Bo Öberg, and Anders Broberg.
March 5, 2020: The PCT application for ULT3 (PCT/SE2019/050789) was published.
February 18, 2020: The intention to grant the ULT3 patent in SE was issued.
December 17, 2019: A paper in the scientific journal Molecules was published: Antibacterial isoquinoline alkaloids from the fungus Penicillium spathulatum Em19. Molecules 2019, 24, 4616; doi:10.3390/molecules24244616. Authors: Nord, C., Levenfors, J.J., Bjerketorp, J., Sahlberg, C., Guss, B., Öberg, B., and Broberg, A.
November 12, 2019: The grant of the ULT1 patent in the US was published.
December 12, 2018: Private placements of 13.5 MSEK.
September 11, 2018: The grant of the ULT2 patent in Sweden was published.
August 28, 2018: Swedish patent application (ULT3) submitted concerning cyclic peptides.
May 24, 2018: Continuation in part (ULT2) submitted in USA concerning new methods of treating bacterial infections.
May 24 - June 1, 2018: National patent applications (ULT1) submitted in USA, Japan, Australia, Canada, China and Europe, concerning new compounds for treating bacterial infections.
May 10 - June 19, 2018: National patent applications (ULT2) submitted in USA, Japan, Australia, Canada, China and Europe, concerning new methods of treating bacterial infections.
April 16, 2018: Divisional Patent Application to ULT2 filed in Sweden.
November 13, 2017: Ultupharma joined Beam Alliance.
October 30, 2017: A publication in Journal of Natural Products, 2017, 80, 2997-3002: Antibacterial 3,6-Disubstituted 4-Hydroxy-5,6-dihydro-2H-pyran-2-ones from Serratia plymuthica MF371-2. doi: 10.1021/acs.jnatprod.7b00565. Authors: Joakim Bjerketorp, Jolanta J. Levenfors, Christer Sahlberg, Christina L. Nord, Pierre F. Andersson, Bengt Guss, Bo Öberg and Anders Broberg.
October 3, 2017: The grant of the ULT1 patent in Sweden was published.
August 3, 2017: PCT application (ULT2) concerning new compunds and methods of treating bacterial infections published as WO 2017/131576, available e.g. from http://www.epo.org
June 27, 2017: A publication in Molecules 2017, 22 (7), 1072. Labradorins with Antibacterial Activity Produced by Pseudomonas sp. doi: 10.3390/molecules22071072Authors: Anders Broberg, Joakim Bjerketorp, Pierre Andersson, Christer Sahlberg and Jolanta J. Levenfors.
June 8, 2017: PCT application (ULT1) concerning new compunds and methods of treating bacterial infections published as WO 2017/095319, available e.g. from http://www.epo.org
February 25, 2017: Private placements of 15 milj SEK.
January 27, 2017: PCT application (ULT2) submitted concerning new methods of treating bacterial infections.
December 2, 2016: PCT application (ULT1) submitted concerning new compounds for treating bacterial infections.